[go: up one dir, main page]

AR070540A1 - Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer. - Google Patents

Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.

Info

Publication number
AR070540A1
AR070540A1 ARP090100694A ARP090100694A AR070540A1 AR 070540 A1 AR070540 A1 AR 070540A1 AR P090100694 A ARP090100694 A AR P090100694A AR P090100694 A ARP090100694 A AR P090100694A AR 070540 A1 AR070540 A1 AR 070540A1
Authority
AR
Argentina
Prior art keywords
het
alq
hal
indicates
nhet
Prior art date
Application number
ARP090100694A
Other languages
English (en)
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of AR070540A1 publication Critical patent/AR070540A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos derivados de benzonaftiridinilo y análogos de los mismos, y procesos para preparar los mismos. Los compuestos son utiles en el tratamiento de enfermedades sensibles a la inhibicion, regulacion o modulacion de la transduccion de senales de cinasas. Reivindicacion 1: Un compuesto de acuerdo con la formula (1) en donde W se selecciona de Hal, Ar-alq, Het-alq, O, OH, SH, S(O)mZ, S(O)mAr, S(O)mHet, Z, OZ, OAr, OHet, OAlq o NRR'; Q es N o NH para satisfacer la valencia adecuada X se selecciona de N o [N+-O-]; ------- indica un enlace sencillo o doble; R1, R2, R3, R4, R5 y R6 se seleccionan independientemente de hidrogeno, Hal, Z, OZ, OAr, OHet, OH, NRR', Ar, Ar-alq, Het, Het-alq, S(O)mZ, S(O)mAr, S(O)mHet, C(O)mOR, NRC(O)mR', NRSO2R', NRC(O)mNR', (CH2)nOZ o C(O)NRR'; R y R' se seleccionan independientemente de hidrogeno, Z, Ar, Ar-alq, Het, Het-alq, OZ, OAr, S(O)mZ, S(O)mAr o S(O)mHet; Z indica alquilo ramificado o no ramificado C1-10, en la cual 1-7 átomos de H se pueden reemplazar por F, Cl y/o Br, y/o en la cual uno o dos grupos CH2 no adyacentes se pueden reemplazar por grupos O, N, NH, S, SO, SO2, y/o CH=CH, o alquilo cíclico C3-7; Ar indica fenilo, naftilo o bifenilo, cada uno de los cuales es no sustituido o mono-, di- o trisustituido por Hal, Z, OR, N(R)2, SR, NO2, CN, COOR, CON(R)2, NRCOZ, NRSO2Z, SO2N(R)2, S(O)mZ, CO-Het, Het, O[C(R)2]nN(R), O[C(R)2]nHet, NHCOOZ, NHCON(R)2, NHCOO[C(R)2]nN(R)2, NHCOO[C(R)2]pHet, NHCONH[C(R)2]nN(R)2, NHCONH[C(R)2]pHet, OCONH[C(R)2]nN(R)2, OCONH[C(R)2]nHet, CHO y/o COZ; Hal indica Cl, Br, I o F; Het indica independientemente un heterociclo mono-, bi- o tricíclico saturado, no saturado o aromático que tiene 1 a 4 átomos de N, O y/o S; que puede ser no sustituido o mono-, di- o trisustituido por Hal, Z, OR, (CH2)pN( R)2, SR, NO2, CN, COOR, CON(R)2, O[C(R)2]nN(R), O[C(R)2]nHet1, NHCOOZ, NHCON(R)2, NHCOO[C(R)2]nN(R)2, NHCOO[C(R)2]nHet, NHCONH[C(R)2]nN(R)2, NHCONH[C(R)2]nHet, OCONH[C(R)2]nN(R)2, OCONH[C(R)2]nHet, NRCOZ, NRSO2Z, SO2N(R)2, S(O)mZ, CO-Het, CHO, COZ, =S, =NH, =NZ, oxi (-O-) y/o =O (oxígeno de carbonilo); alq indica alquileno ramificado o no ramificado C1-10, en el cual 1-7 átomos de H se pueden reemplazar por F, Cl, y/o Br, y/o en el cual uno o dos grupos CH2 no adyacentes se pueden reemplazar por grupos O, S, SO, SO2, NH, NZ, CH=CH y/o C:::C, y que se pueden sustituir por Hal, OR, SR, Ar y/o =O; m es 0, 1 o 2; n es 0, 1, 2, 3, 4, 5 o 6; p es 0, 1, 2, 3 o 4, y en donde al menos uno de R1 a R6 no es H, y un profármaco, derivado, solvato, sal, tautomero y estereoisomero farmacéuticamente aceptable del mismo, incluyendo mezclas de los mismos en todas las proporciones.
ARP090100694A 2008-02-28 2009-02-27 Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer. AR070540A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6749208P 2008-02-28 2008-02-28

Publications (1)

Publication Number Publication Date
AR070540A1 true AR070540A1 (es) 2010-04-14

Family

ID=40622992

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100694A AR070540A1 (es) 2008-02-28 2009-02-27 Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.

Country Status (10)

Country Link
US (1) US8735584B2 (es)
EP (1) EP2254889B1 (es)
JP (1) JP5529761B2 (es)
CN (1) CN101952287B (es)
AR (1) AR070540A1 (es)
AU (1) AU2009219376B2 (es)
CA (1) CA2712990C (es)
ES (1) ES2401550T3 (es)
IL (1) IL207415A (es)
WO (1) WO2009108670A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3247030B2 (ja) 1995-05-18 2002-01-15 新日本製鐵株式会社 H形鋼のフランジ幅制御方法およびその装置
AU2009333653B2 (en) * 2008-12-17 2015-09-10 Merck Patent Gmbh C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
GB2486631A (en) * 2010-12-01 2012-06-27 Univ Sheffield Phenol/quinone boronic acids/esters and method of preparation thereof
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
BR112013022671A2 (pt) * 2011-03-08 2016-07-19 Basf Se processo para a preparação de aminas primárias, e, uso de um catalisador complexo
CA2844588A1 (en) * 2011-08-10 2013-02-14 Merck Patent Gmbh Pyrido-pyrimidine derivatives
MX2015001424A (es) 2012-07-28 2016-03-09 Calitor Sciences Llc Compuestos pirazolona sustituidos y metodos de uso.
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
AU2014214324B2 (en) 2013-02-07 2018-07-19 Prexton Therapeutics Sa Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4
WO2017070719A2 (en) * 2015-10-22 2017-04-27 Mangosuthu University Of Technology Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of cyp17a1 and cyp19a1
CA3056886A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
TWI853814B (zh) 2018-05-31 2024-09-01 南韓商C&C新藥研究所 雜環衍生物及其用途
HUE073437T2 (hu) 2018-12-28 2026-01-28 Deciphera Pharmaceuticals Llc CSF1R gátlók tenoszinoviális óriássejtes tumorok kezelésében való alkalmazásra
CN116462677A (zh) * 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
WO2024012308A1 (zh) * 2022-07-15 2024-01-18 上海和誉生物医药科技有限公司 一种prmt5抑制剂,其制备方法和在药学上的应用
CN117209426A (zh) * 2023-09-11 2023-12-12 广西中医药大学 类两面针碱-磺胺衍生物及其制备方法和应用
TW202542127A (zh) 2023-12-08 2025-11-01 美商迪賽孚爾製藥有限公司 激酶抑制劑之固態形式
US20250205161A1 (en) 2023-12-08 2025-06-26 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025231106A1 (en) 2024-05-01 2025-11-06 Deciphera Pharmaceuticals, Llc Csf-1r inhibitors and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU719434B2 (en) 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
WO2002044183A2 (en) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors

Also Published As

Publication number Publication date
US20110053906A1 (en) 2011-03-03
CN101952287A (zh) 2011-01-19
ES2401550T3 (es) 2013-04-22
AU2009219376B2 (en) 2014-09-25
IL207415A0 (en) 2010-12-30
JP5529761B2 (ja) 2014-06-25
JP2011513322A (ja) 2011-04-28
US8735584B2 (en) 2014-05-27
CA2712990A1 (en) 2009-09-03
EP2254889A1 (en) 2010-12-01
CA2712990C (en) 2016-09-27
WO2009108670A1 (en) 2009-09-03
CN101952287B (zh) 2013-11-27
AU2009219376A1 (en) 2009-09-03
EP2254889B1 (en) 2012-12-19
IL207415A (en) 2016-12-29

Similar Documents

Publication Publication Date Title
AR070540A1 (es) Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.
AR066770A1 (es) Derivados de piridazinona
AR066543A1 (es) Derivados de piridazinona
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
PE20090060A1 (es) ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR
AR066892A1 (es) Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit
MX9203122A (es) Compuestos analogos de distamicina a y composiciones farmaceuticas que los contienen.
AR062050A1 (es) Derivados de amina utiles como agentes anti-cancerigenos
AR055772A1 (es) Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto
AR068657A1 (es) Derivados de piperidina y piperazina
AR068658A1 (es) Derivados de tiazol
AR057214A1 (es) Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas.
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR072860A1 (es) Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
AR071208A1 (es) Derivados de piridazinona
PE20240886A1 (es) Compuestos espirociclicos
WO2021046523A8 (en) Composition of matter for use in organic light-emitting diodes
EA200970582A1 (ru) ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH
AR075122A1 (es) Derivados de piridazinona
WO2023151560A1 (en) Bicyclic heteroaryl compounds and uses thereof
AR071217A1 (es) Derivados bencimidazol
ES2849153T3 (es) 2H-Selenofeno[3,2-h]cromenos antimetastásicos, síntesis de los mismos, y métodos de uso de tales agentes
MY129329A (en) 6,7-DIHYDRO-5H-PYRAZOLO[1,2-a]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES
US4125547A (en) 12,13(E)-Didehydro-13,14-dihydro-9-deoxy-PGD1 compounds

Legal Events

Date Code Title Description
FG Grant, registration